SK Hynix Bonus Dispute Deepens as Union Rejects Stock-Based Payout Proposal 
BHP Port Hedland Strike Set to Proceed as Wage Talks Continue 
Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
Jetstar to Charge for Overhead Cabin Bags From February 
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
Toyota Raises FY2027 Outlook, Announces ¥1 Trillion Buyback Despite Q1 Profit Dip 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets 
CANTON, Mass., March 16, 2018 -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will present at the following investor conferences in March:
- The Oppenheimer & Company 28th Annual Healthcare Conference on Wednesday, March 21st at 9:10 a.m. ET in New York City
- The Needham 17th Annual Healthcare Conference on Wednesday, March 28th at 10:30 a.m. ET in New York City
About Collegium Pharmaceutical, Inc.
Collegium is a specialty pharmaceutical company focused on becoming the leader in responsible pain management by developing and commercializing innovative, differentiated products for patients suffering from pain.
About Xtampza ER
Xtampza® ER is Collegium’s first product utilizing the DETERx technology platform. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Contact:
Alex Dasalla
[email protected]
